Drug Profile
Oxybutynin transdermal - Schwarz Pharma
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Schwarz Pharma
- Class Alkynes; Antispasmodics; Carbocyclic acids; Cyclohexanes; Diethylamines; Esters; Mandelic acids; Skin disorder therapies; Small molecules
- Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Urinary incontinence
Most Recent Events
- 24 Aug 2001 Discontinued-Clinical for Urinary incontinence in USA (Transdermal)
- 22 Jun 2000 Investigation in Urinary incontinence in USA (Transdermal)
- 09 Jul 1999 New profile